Clinical Trial

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-1403. The study will also measure what happens to MK-1403 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-17; most recent amendment 2026-07-10.
Status change: Not Yet Recruiting → Recruiting 2026-01-13
Trial Details
NCT Number NCT07242469
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Diabetes Mellitus, Type 2
Enrollment 52 participants
Start Date 2025-12-22
Primary Completion 2026-09-03 (estimated)
Study Completion 2026-09-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-31